darizmetinib
AssetAlso HRX-0215, LN-3348
Inhibits MKK4 to promote hepatocyte proliferation and liver regeneration.
- Stage
- Human trials
- Modality
- Small molecule
- Target
- MAP2K4
- 1
- Indication
- 0
- Trials
- 1
- Developer
Indications
1Post-hepatectomy liver failure
Human trials, longevity.technology, 8 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Evidence for its targets1
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.